Status:
COMPLETED
Safety and Efficacy of AIN457 in Noninfectious Uveitis
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Non-infectious Uveitis
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
This study was performed to evaluate the efficacy and safety of AIN457 for patients with active uveitis that requires systemic immunosuppression.
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Active uveitis (i.e., uveitis that is not in remission).
- Intermediate uveitis, posterior uveitis, or panuveitis must be sufficiently severe that systemic immunosuppression is indicated.
- Exclusion criteria:
- Active infection.
- Weight must not be greater that 120kg.
- Other protocol-defined inclusion/exclusion criteria may apply
Exclusion
Key Trial Info
Start Date :
June 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2013
Estimated Enrollment :
76 Patients enrolled
Trial Details
Trial ID
NCT00685399
Start Date
June 1 2008
End Date
September 1 2013
Last Update
July 17 2017
Active Locations (23)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Investigative Site
Beverly Hills, California, United States, 90211
2
Novartis Investigative Site
Los Angeles, California, United States, 90033
3
Novartis Investigative Site
Sacramento, California, United States, 95819
4
Novartis Investigative Site
Denver, Colorado, United States, 80210